FORM #149	
16 1 18 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FORMATION DISCLOSURE STAT
a mile	IN AN APPLICATION
MAY 0 6 YOUR	(Use several sheets if necessary)
Ed .	7

IATION DISCLOSURE STATEMENT

Docket Number: 14233.19USWO Application Number: 10/502,119

Applicant: Lautt et al. Filing Date: July 21, 2004

Group Art Unit: 1632

BADEMA			U.S	. PATENT DOCUMENTS	·			
EXAMINER	DOCUMENT NO.		DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
INITIAL		-+						
•								
				EIGN PATENT DOCUME	T	SUBCLASS	TRANS	LATION
	DOCUMENT NO. D.		DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
							125	
	1 020 452 1 142 879 02/13798 02/24698		06/26/1998	EP				
			12/20/1999	EP		<u> </u>		
			02/21/2002	wo	-	<b> </b>		
			03/28/2002	wo				
			04/10/2003	wo				1
		OTHER	DOCUMENT	S (Including Author, Title,	Date, Pertinen	Pages, Etc.)		
	1 1	Obacity o	md Metabolism.	lin resistance and β-cell dys 3: 219-229.				
	+	Laura et al. (1908) "Rapid insulin sensitivity test (RIST)", Can. J. Physiol. Pharmacol., 76: 1080-1086.						
		Lautt (19	99) "The HISS:	story overview: a novel hep-	atic neurohum 77: 553-562.	oral regulation of p	eripheral insu	lin sensitivii
		Nakaya	et al. (1999) "Cil	lostazol, a phosphodiesteras Rat, a model osf spontaneou	e inhibitor, im s NIDDM", D			
		Davis st	-1 (1006) "End	lothelial Nitric Oxide Produ	ction and Insu	lin Sensitivity", Cir	culation, 93:	1331-1333.

23552
ATENT TRADEMARK OFFICE

DATE CONSIDERED 03/14/2008 /Sahar Javanmard/ EXAMINER EXAMINER. Initial if reference considered, whether or not classion is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.